drugset / Trial / NCT03936959
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3434172, a PD-1/PD-L1 bispecific antibody, in participants with advanced solid tumors.
Timeline
- Start
- 2019-05-24
- Primary completion
- 2020-03-30
- Completion
- 2021-04-29
Outcome
Outcome not reported
Stopped: “Study did not achieve its primary objective due to early termination of the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REOZALIMAB | Monoclonal antibody | 10 mg | Intravenous |
| Subject | REOZALIMAB | Monoclonal antibody | 30 mg | Intravenous |
| Subject | REOZALIMAB | Monoclonal antibody | 100 mg | Intravenous |
Indications
No indication recorded.